CoreCap Advisors’s Medifast MED Stock Holding History

CoreCap Advisors’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3	Closed	-$1K	–	1451
2022 Q2	$1K	Buy	+3	New	+$537	﹤0.01%	2017

Other funds holding MED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

CoreCap Advisors's MED Position: Q3 2022 in Review

CoreCap Advisors sold out of Medifast (MED) in Q3 2022, closing a stake of 3 shares — an estimated $1K sold.

CoreCap Advisors first reported a position in MED in Q2 2022 and held it in 1 quarter. The position peaked at $1K in Q2 2022. 263 funds tracked by Wall St. Rank hold MED as of Q3 2022.

CoreCap Advisors reported no remaining Medifast position as of Q3 2022 after selling out during the quarter.
CoreCap Advisors sold 3 Medifast shares in Q3 2022, an estimated $1K.
CoreCap Advisors first reported a position in Medifast in Q2 2022 and held it in 1 quarter.
CoreCap Advisors's Medifast position peaked at $1K in Q2 2022.
263 funds tracked by Wall St. Rank held Medifast as of Q3 2022.

Based on CoreCap Advisors's 13F filing for Q3 2022, filed 10 Feb 2023.